¹³¹I/MTX-loaded engineered outer membrane vesicles for sequentially coordinated radio-metabolic-immunotherapy of glioma.

ABSTRACT: The efficacy of radiotherapy for brain tumors is limited by tumor cell radio-resistance and the immunosuppressive microenvironment, which often counteracts the immunogenic effects of radiation-induced antitumor responses. To address this, we developed statherin-enriched engineered outer membrane vesicles (OMVs), co-labeled with the radionuclide ¹³¹I and loaded with the metabolic inhibitor methotrexate (MTX), termed ¹³¹I-O/M-P, to enable integrated radiotoxicity, metabolic intervention, and immune activation. Upon delivery of ¹³¹I-O/M-P to the tumor site, ¹³¹I promptly emits β-rays that induce DNA double-strand breaks, triggering immunogenic cell death (ICD) and the release of damage-associated molecular patterns (DAMPs), thereby initiating antitu

SUBMITTER: Liang M 

PROVIDER: S-EPMC12817699 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature